The FDA's recent authorization of Omicron-specific boosters has sparked questions about efficacy data and cost effectiveness in certain populations.
The FDA's recent authorization of Omicron-specific boosters has sparked questions about efficacy data and cost effectiveness in certain populations.
The FDA's recent authorization...